Top Selected Abstracts

• Long-term outcomes after appendectomy for maintenance of remission in ulcerative colitis: Five-year NL-results from the ACCURE randomized controlled trial

• PROFILE 4-year follow-up shows that early effective “top-down” therapy is associated with reduced long-term Crohn’s disease complications

• Ileocaecal resection versus infliximab for ileal Crohn’s disease: 10-year follow-up of the LIR!C trial

• The Tasty&Healthy whole food diet improves calprotectin in high risk first-degree relatives of patients with Crohn’s disease (FDRs): The PIONIR randomized controlled prevention cross-over trial

• Efficacy and safety of vedolizumab combined with upadacitinib as an 8-week induction strategy in moderate-to-severe ulcerative colitis: a multicenter, randomized controlled trial

• Results from the STENOVA trial: A Phase 2a, randomized, placebo-controlled, double-blind study to assess the safety, pharmacokinetics (PK), and pharmacodynamics of ontunisertib (AGMB-129) in patients with Fibrostenotic Crohn’s Disease (FSCD)

• Who benefits from endotherapy in Crohn’s disease strictures? Predictors of recurrence, need for reintervention, and surgery from the Balloon Dilation versus Endoscopic Stricturotomy for Crohn’s Disease (BEST-CD) randomised controlled trial

• Randomised controlled trial of withdrawal of thiopurines in patients with IBD switching from intravenous to subcutaneous infliximab: Results of the MINIMISE study

• Faecal microbiota transplantation for active Crohn’s disease: The MIRO (Microbial Restoration) randomised placebo-controlled trial.

• Combination treatment with adalimumab and partial enteral nutrition compared with adalimumab monotherapy in adults with active Crohn’s disease: The BIOPIC study

• Ustekinumab for Fistulizing Perianal Crohn’s Disease: week-48 results from the USTAP Randomized Placebo-Controlled Trial

• NORDTREAT: a randomised, multicentre, biomarker-strategy design, open-label, controlled trial of top-down versus clinical management in newly diagnosed IBD

• Real-world effectiveness and safety of etrasimod in Ulcerative Colitis: interim analysis of the EFFECT-UC study

• Evaluation of transmural healing in patients with moderately to severely active Crohn’s disease shows early efficacy of vedolizumab: VECTORS week 14 interim analysis

Watch Full Webinar (60 mins)

Click below for full slide deck (EN & FR)

Scientific Committee:

Waqqas Afif, MD | Montreal, QC
Jeff McCurdy, MD | Ottawa, ON
Sally Lawrence, MD | Vancouver, BC
Neeraj Narula, MD | Hamilton, ON
Reena Khanna, MD | London, ON
Cynthia Seow, MD | Calgary, AB

Abstracts Selected for Webinar

Long-term outcomes after appendectomy for maintenance of remission in ulcerative colitis: Five-year NL-results from the ACCURE randomized controlled trial

I. Van Dijk, E. Visser, G. D’Haens, W. Bemelman, C.J. Buskens, AUMC

Slides created by: Cynthia Seow

PROFILE 4-year follow-up shows that early effective “top-down” therapy is associated with reduced long-term Crohn’s disease complications

N. Noor, H. Zheng, M.T. Sharip, J. Lee, D. Robertson, M. Parkes, PROFILE Study Group

Slides created by: Reena Khanna

Ileocaecal resection versus infliximab for ileal Crohn’s disease: 10-year follow-up of the LIR!C trial

A. Haanappel, L. Oldenburg, M. Ali, C. Bosman, C.J. Buskens, C. Ponsioen, G. D’Haens, W. Bemelman, LIR!C study group

Slides created by: Cynthia Seow

Efficacy and safety of vedolizumab combined with upadacitinib as an 8-week induction strategy in moderate-to-severe ulcerative colitis: a multicenter, randomized controlled trial

H. Wu, L. Wu, T. Xie, J. Wu, H. Chen, Q. Yu, X. Cao, M. Zhi, J. Yao

Slides created by: Reena Khanna

Non-Webinar Abstracts

The Tasty&Healthy whole food diet improves calprotectin in high risk first-degree relatives of patients with Crohn’s disease (FDRs): The PIONIR randomized controlled prevention cross-over trial

D. Turner, S. Kenigsberg, L. Plotkin, Y. Aharoni-Frutkoff, M. Sokolik, G. Focht, W. Turpin, A.M. Waslyk, O. Ledder, A. Griffiths, I. Martincevic, H. Huynh, L. Godny, I. Avni Biron, J. Tinoco da Silva Torres, S.H. Lee, K. Croitoru

Slides created by: Sally Lawrence

Results from the STENOVA trial: A Phase 2a, randomized, placebo-controlled, double-blind study to assess the safety, pharmacokinetics (PK), and pharmacodynamics of ontunisertib (AGMB-129) in patients with Fibrostenotic Crohn’s Disease (FSCD)

F. Rieder, B.G. Feagan, C. Lu, A. Poulsen, W. Reinisch, J. Kierkuś, E. Ricart Gomez, P.J. Stiers, K. Thys, R. Brys, M. Brill, C. Fleurinck, R. Van Heeswijk, A. Saez, T. Van Kaem, P. Wiesel

Slides created by: Reena Khanna

Who benefits from endotherapy in Crohn’s disease strictures? Predictors of recurrence, need for reintervention, and surgery from the Balloon Dilation versus Endoscopic Stricturotomy for Crohn’s Disease (BEST-CD) randomised controlled trial (NCT05521867)

P. Pal, K. Pooja, R. Gupta, M. Tandan, D.N. Reddy

Slides created by: Neeraj Narula

Randomised controlled trial of withdrawal of thiopurines in patients with IBD switching from intravenous to subcutaneous infliximab: Results of the MINIMISE study

P.M. Irving, A. Centritto, X.Y. Choon, J.H. Yeo, W. Blad, A. Talbot, A.L. Fitzgerald, E. Whitehead, A. Elford, M. Colwill, S. Baillie, R. Pramanik, S. Ayis, A. Goubar, M. Arenas Hernandez, J. Cordle, C. Lees, R. Pollok, S. Sebastian, R. Dart, M. Samaan, P. Harrow

Slides created by: Sally Lawrence

Faecal microbiota transplantation for active Crohn’s disease: The MIRO (Microbial Restoration) randomised placebo-controlled trial

S. Fehily, E.K. Wright, D. Bogatic, A. Wilson-O’Brien, C. Basnayake, A. Stanley, E. Marks, E. Russell, Y. Rong, I. Gory, Z. Ardalan, A. Hamilton, M. Morrison, A. Thompson, R.V. Bryant, S.P. Costello, M.A. Kamm

Slides created by: Neeraj Narula

Combination treatment with adalimumab and partial enteral nutrition compared with adalimumab monotherapy in adults with active Crohn’s disease: The BIOPIC study

B. White, I. Campbell, C. Fandinga, C. Kerbiriou, J. Clowe, A. Jatkowska, E. Brownson, S. Milling, G.T. Ho, C. Mowat, E. Robertson, D. Gaya, A. Kefayat, S. Din, J.P. Seenan, J. Macdonald, K. Gerasimidis

Slides created by: Sally Lawrence

Ustekinumab for Fistulizing Perianal Crohn’s Disease: week-48 results from the USTAP Randomized Placebo-Controlled Trial

P. Wils, S. Nancey, E. Messmer, A. Bourreille, A. Buisson, L. Caillo, L. Vuitton, R. Altwegg, X. Hebuterne, O. Ernst, P. Meunier, V. Laurent, D. Laharie, E. Vicaut, L. Peyrin-Biroulet, GETAID group

Slides created by: Cynthia Seow

NORDTREAT: a randomised, multicentre, biomarker-strategy design, open-label, controlled trial of top-down versus clinical management in newly diagnosed IBD

D. Bergemalm, D. Füchtbauer, M. Rejller, L. Davíðsdóttir, A. Fejrskov, C.R. Hedin, C. Bache-Wiig Mathisen, G. Hupperz-Hauss, A. Carstens, V. Kristensen, H. Hjortswang, T.B. Aabrekk, M. Carlson, S.O. Frigstad, J.D. Söderholm, R. Christensen, V.C. Andersen, D. Repsilber, J. Kjeldsen, M. Høivik, J. Halfvarson

Slides created by: Neeraj Narula

Real-world effectiveness and safety of etrasimod in Ulcerative Colitis: interim analysis of the EFFECT-UC study

P.M. Irving, R. Battat, S. Mehta, P. Harrow, D. Gaya, A. Walsh, T. Kucharzik, C. Maaser, E. Jörgensen, Y. Leung, E. Binder, M. Kudela, B. Sahin, T. Meng, A. Falsafi, K. Wosik, S. Hahne, U. Helwig

Slides created by: Waqqas Afif

Evaluation of transmural healing in patients with moderately to severely active Crohn’s disease shows early efficacy of vedolizumab: VECTORS week 14 interim analysis

V. Jairath, S.K. Vuyyuru, C. Ma, G. Zou, B. Neustifter, C. Agboton, I. Romo Bautista, J.J. Wu, H.J. Jiang, M. Allocca, Y.K. An, J. Begun, R.V. Bryant, S. Danese, M.C. Dubinsky, M. Freire, K.L. Novak, R. Panaccione, A. Pudipeddi, D.T. Rubin, B.E. Sands, M.P. Sparrow, S.A. Taylor, K.B. Gecse, C. Maaser, B.G. Feagan, R.L. Wilkens

Slides created by: Jeff McCurdy